A5033278652- Veterinary Oncology Research
- Nuclear Structure and Function
- Virus-based gene therapy research
- Protein Degradation and Inhibitors
- dental development and anomalies
- RNA modifications and cancer
- RNA Research and Splicing
- Neuroblastoma Research and Treatments
- PARP inhibition in cancer therapy
- Thyroid Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Circular RNAs in diseases
- Endoplasmic Reticulum Stress and Disease
- Ubiquitin and proteasome pathways
- Head and Neck Surgical Oncology
- RNA regulation and disease
- interferon and immune responses
- Infectious Diseases and Mycology
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Fibroblast Growth Factor Research
- Research on Leishmaniasis Studies
- Tumors and Oncological Cases
- Leptospirosis research and findings
Children's Hospital of Philadelphia
2022-2025
Veterinary Medical Teaching Hospital
2021-2022
University of California, Davis
2021-2022
University of Wisconsin–Madison
2019-2021
University of Pennsylvania
2017-2019
Increasing evidence indicates that the tumor microenvironment plays a critical role in regulating biologic behavior of breast cancer. In veterinary oncology, there is need for improved prognostic markers to accurately identify dogs at risk local and distant (metastatic) recurrence mammary gland carcinoma therefore would benefit from adjuvant therapy. Collagen density fiber organization have been shown regulate progression both mouse human tumors, with certain collagen signatures predicting...
The importance of cellular context to the synergy DNA damage response (DDR)-targeted agents is important for tumors with mutations in DDR pathways, but less well-established driven by oncogenic transcription factors. In this study, we exploit widespread transcriptional dysregulation EWS-FLI1 factor identify an effective DDR-targeted combination therapy Ewing sarcoma.
Abstract Neuroblastoma (NB) is a malignant cancer that originates in the developing peripheral nervous system and accounts for ∼15% of all childhood deaths. Some NBs are easily cured, but those classified as high risk require treatment includes chemotherapy, surgery, autologous stem cell transplant, radiation, immunotherapy with antibodies targeting disialoganglioside GD2. Despite this extensive therapy, only ∼50% children survive. Even these high-risk cases, most NB cells respond to initial...
Sorafenib is a multi-kinase small molecule inhibitor that targets serine/threonine and tyrosine kinases including the RAF kinase family, VEGFR-2, PDGFR. The aim of this study was to evaluate systemic pharmacokinetics previously defined tolerable oral dose sorafenib in tumor-bearing dogs. Six client-owned dogs with cytologic or histologic diagnosis cancer were enrolled open-label, tolerability study. Dogs administered at an intended 3 mg/kg serum samples obtained for analysis concentrations...
Olfactory neuroblastoma (ONB) is a rare intranasal neoplasm in both dogs and humans. Similar clinical presentation overlapping histologic immunohistochemical features of ONB with other neoplasms can make diagnosis treatment neoplasia challenging. Furthermore, part because their rarity, there lack reporting on therapeutic regimen for these neoplasms. In humans, initial debulking surgery usually followed by radiation therapy. Here we report the histologic, immunohistochemical, ultrastructural...
Abstract Background While rare, multiple individual case reports have described mixed thyroid tumours in dogs containing both epithelial and mesenchymal neoplastic components. Objectives In this retrospective series, we describe the clinical presentation, treatment outcome of 14 canine with concurrent populations. Methods Fourteen cases were retrospectively abstracted from nine institutions. Histopathologic samples collected 10/14 reviewed by a single board‐certified anatomic pathologist....
Objectives The aims of this study were to evaluate the safety mustargen, vincristine, procarbazine and prednisone (MOPP) chemotherapy in treatment relapsed or refractory feline lymphoma, determine overall response rate median remission time with protocol. Methods medical records 38 cats lymphoma treated MOPP at three institutions (University Pennsylvania, Animal Medical Center, VCA Western Veterinary Specialist Emergency Centre) examined. Information evaluated included patient signalment,...
Abstract A 3‐year‐old dog was referred to the Veterinary Medical Teaching Hospital of University California‐Davis for further evaluation episodes epistaxis 1‐year duration and peripheral lymphadenopathy. The patient had a history atopic dermatitis with no travel outside California. Hyperglobulinemia polyclonal gammopathy noted on serum protein electrophoresis. Microscopic bone marrow aspirate sample revealed many free intra‐cellular amastigotes Leishmania sp. that confirmed by qPCR as L...
Abstract Background: Ewing sarcoma (ES) is a malignant bone tumor characterized by the oncogenic fusion protein EWS-FLI1. EWS-FLI1 acts as an aberrant transcription factor, inducing and silencing genes involved with increasing cell proliferation survival. We have previously shown that lurbinectedin, trabectedin analog, effectively inactivates transcriptional activity of redistributing it within nucleus to nucleolus. Interestingly, this process activates gene signature like DNA damage...
<div>AbstractPurpose:<p>The importance of cellular context to the synergy DNA damage response (DDR)-targeted agents is important for tumors with mutations in DDR pathways, but less well-established driven by oncogenic transcription factors. In this study, we exploit widespread transcriptional dysregulation EWS-FLI1 factor identify an effective DDR-targeted combination therapy Ewing sarcoma.</p>Experimental Design:<p>We used matrix drug screening evaluate between a...
<p>Supplementary Figures S1-S15 and Legends</p>
<div>AbstractPurpose:<p>The importance of cellular context to the synergy DNA damage response (DDR)-targeted agents is important for tumors with mutations in DDR pathways, but less well-established driven by oncogenic transcription factors. In this study, we exploit widespread transcriptional dysregulation EWS-FLI1 factor identify an effective DDR-targeted combination therapy Ewing sarcoma.</p>Experimental Design:<p>We used matrix drug screening evaluate between a...
<p>Supplementary Figures S1-S15 and Legends</p>
Abstract OBJECTIVE To determine whether, in dogs with naïve multicentric lymphoma, neutrophilia at the time of initial diagnosis was associated progression-free survival (PFST) or overall response rate (ie, percentage a complete partial remission) and whether neutrophil-to-lymphocyte ratio PFST. ANIMALS 30 lymphoma (including 16 treated cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP]–based protocol) 37 historical control without CHOP-based protocol. PROCEDURES Medical records...
Cyclophosphamide (CP) is an alkylating agent commonly included in multi-drug treatment protocols for canine cancer. As a prodrug, CP requires hepatic metabolism activation to the intermediate compound 4-hydroxycyclophosphamide (4-OHCP) which then spontaneously forms phosphoramide mustard. frequently administered fractionated manner, with total dose given over multiple days. reported cause auto-induction of humans, faster clearance and relatively increased 4-OHCP formation following versus...